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Abstract
Increased levels of a soluble form of endoglin (sEng) circulating in plasma have been de-
tected in various pathological conditions related to cardiovascular system. High concentra-
tion of sEng was also proposed to contribute to the development of endothelial dysfunction,
but there is no direct evidence to support this hypothesis. Therefore, in the present work we
analyzed whether high sEng levels induce endothelial dysfunction in aorta by using trans-
genic mice with high expression of human sEng. Transgenic mice with high expression of
human sEng on CBAxC57Bl/6J background (Sol-Eng+) and age-matched transgenic litter-
mates that do not develop high levels of human soluble endoglin (control animals in this
study) on chow diet were used. As expected, male and female Sol-Eng+ transgenic mice
showed higher levels of plasma concentrations of human sEng as well as increased blood
arterial pressure, as compared to control animals. Functional analysis either in vivo or ex
vivo in isolated aorta demonstrated that the endothelium-dependent vascular function was
similar in Sol-Eng+ and control mice. In addition, Western blot analysis showed no differ-
ences between Sol-Eng+ and control mice in the protein expression levels of endoglin, en-
dothelial NO-synthase (eNOS) and pro-inflammatory ICAM-1 and VCAM-1 from aorta. Our
results demonstrate that high levels of soluble endoglin alone do not induce endothelial dys-
function in Sol-Eng+ mice. However, these data do not rule out the possibility that soluble
endoglin might contribute to alteration of endothelial function in combination with other risk
factors related to cardiovascular disorders.
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INTRODUCTION
Endoglin/CD105 (Eng) is an accessory type III receptor for several members of the transform-
ing growth factor-β (TGF-β) superfamily of proteins. This homodimeric, 180 kDa, transmem-
brane glycoprotein is considered to play an eminent role in hematopoiesis, angiogenesis,
cardiovascular development and vascular tone [1]. Endoglin is expressed predominantly in en-
dothelial cells, but it can also be detected in various other cells, including smooth muscle cells,
mesenchymal and hematopoietic stem cells, monocytes/macrophages, placental syncytiotro-
phoblasts and fibroblasts [2].
In addition to membrane-bound endoglin, increased levels of a soluble form of endoglin
(sEng) have been detected in plasma in various pathological conditions related to the cardio-
vascular system. Circulating sEng represents the NH2-terminal cleavage product of full-length
membrane-bound endoglin [3] and was proposed to be cleaved from the intact membrane
form of several cell types including endothelial cells and trophoblasts by matrix metalloprotei-
nase-14 (MMP-14 or MT-1) [4,5].
There is a number of reports suggesting that soluble endoglin may be regarded as a bio-
marker of endothelial dysfunction, for example in pre-eclampsia [3], atherosclerosis [6,7],
hypercholesterolemia [8], diabetes mellitus and hypertension [9] and chronic coronary artery
disease [10]. Because in all of these pathologies the endothelial dysfunction plays an important
role, it was also proposed that high levels of soluble endoglin might represent a hallmark of en-
dothelial dysfunction contributing to the development of numerous cardiovascular diseases,
including pre-eclampsia and atherosclerosis [11]. On the other hand, it was also demonstrated
that soluble endoglin is able to modify TGF-β-dependent signaling in vascular endothelium
[12]. Despite being related to several cardiovascular pathologies, it is still unclear whether solu-
ble endoglin represents a mere biomarker or it is mechanistically involved in vascular patholo-
gy via e.g. induction of endothelial dysfunction.
The increased expression of cell adhesion molecules, the impairment of NO bioavailability
and NO-dependent vasodilatation are the general hallmarks of endothelial dysfunction, the
crucial step in the pathogenesis of atherosclerosis [13–15]. Interestingly, it was demonstrated
that soluble endoglin increases the expression of cell adhesion molecules, the number of rolling
leukocytes and impairs endothelial dependent vascular function [12]. Furthermore, we have re-
cently observed that soluble endoglin impairs leukocyte rolling and binding to endothelium
“in vitro” [16].
In order to study the pathogenic role of soluble circulating form of Eng, a transgenic mouse
model expressing human soluble endoglin (Sol-Eng+) has been recently generated. The Sol-
Eng+mice exhibit a pre-eclampsia-like phenotype, including hypertension, small pup size, pro-
teinuria and renal damage [5].
Considering a possible role of soluble endoglin in the development of systemic endothelial
dysfunction, in the present work, we have assessed whether in Sol-Eng+mice the endothelial
dysfunction in aorta can be detected, as compared to their transgenic littermates with low levels
of soluble endoglin.
MATERIALS ANDMETHODS
Animals and study design
Amouse line that overexpresses human soluble endoglin (Sol-Eng+) on the CBAxC57BL/6J
background was generated at the Genetically Modified Organisms Generation Unit (University
of Salamanca, Spain), as previously described [5]. Four to six month old Sol-Eng+ male and fe-
male mice with high plasma levels of soluble endoglin and their age matched male and female
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littermates with low plasma levels of soluble endoglin (transgenic mice with low plasma levels
of sEng used as control mice) were used. The animals were housed under a 12-h light cycle and
constant temperature and humidity and had free access to tap water and a standard laboratory
pellet diet.
All experiments were performed in accordance with the directive of the EEC (86/609/EEC)
and the use of animals was approved by the Ethical Committee for the protection of animals
against cruelty at Faculty of Pharmacy in Hradec Kralove, Charles University in Prague (Permit
Number: 21558/2013–2), and the Bioethics Committee of the University of Salamanca (Permit
Number: 006–201400038812).
All surgery procedures were carried out under ketamine/diazepam/atropine or ketamine/
xylazine anesthesia, and all efforts were made to minimize the suffering of the animals.
Analysis of soluble endoglin concentration in plasma
Blood was extracted using a tail tip and plasma levels of human soluble endoglin were deter-
mined by means of Human Endoglin/CD105 Quantikine ELISA Kit (R&D Systems, MN,
USA) according to the instructions of the manufacturer.
Blood Pressure and heart rate measurement
Basal Blood pressure (BP) was recorded in conscious mice with an automated multichannel
system by using the tail-cuff method and a photoelectric sensor (Niprem 546; Cibertec, Spain).
Animals were previously accustomed for several days and measures were collected at the same
hour during at least 3 days, as previously described [17–19]. Acute changes in BP and heart
rate (HR) after drug administration were measured in conscious, freely moving mice by radio-
telemetry techniques as previously described [17]. In brief, after anesthesia of the animals with
a mixture of ketamine 78 mg/Kg, diazepam 6 mg/Kg, and atropine 0.15 mg/Kg; i.p., the carotid
artery of the mouse was accessed with a ventral midline incision, and cannulated with a cathe-
ter attached to a combination pressure transducer, transmitter and battery, all encapsulated in
an implantable microminiaturized electronic monitor (PA-C20, Data Sciences International-
DSI-; MN, USA). The skin was closed with staples and tissue adhesive, and topical antiseptic
was applied. An analgesic, (buprenorphine 0.1 mg/Kg i.m., Buprex, Schering-Plough, Spain)
was given at the end of the surgery. An antibiotic (cefazolin 25 mg/Kg, i.m., Normon, Spain)
was administered at the time of the operation and twice daily during recovery. Approximately
1 mL of normal saline was subcutaneously injected into two or more abdominal sites to assure
adequate postoperative hydration, and the animal was kept in a ventilated and warm environ-
ment for at least 24 h. Each animal was housed individually in a standard polypropylene cage
in a 12:12-h light-dark cycle room, fed standard rodent chow, and given drinking water ad libi-
tum. At least 13 days after recovery from the surgical procedures, the cage was placed over a
radio receiver in a quiet environment, and repeated measurements of basal systolic (SAP) and
diastolic (DAP) arterial pressure and HR were performed in each animal between 10:00 a.m.
and 14:00 p.m., for at least 3 days, to ensure stable pressure record. Data was digitally recorded
on a computer and results were calculated using the software provided by Data Sciences. To as-
sess the acute effects of the substances to be tested, basal SAP and DAP and HR were recorded
for 5 min. Then, animals were given the different substances by i.p. injection in 0.1 mL isotonic
NaCl, and AP and HR were continuously recorded for 30 min. Injection of 0.1 mL of isotonic
NaCl induced a transient increase in AP and HR that disappeared in 1–2 min and was similar
in WT and Sol-Eng+mice; thus, indicating that the effects observed for the different substances
are not due to animal manipulation or differential response to stress between mouse strains.
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PLOS ONE | DOI:10.1371/journal.pone.0119665 March 13, 2015 3 / 13
Substances tested were: acetylcholine 1 μg/Kg, sodium nitroprusside (SNP) 2 mg/Kg, and the
nitric oxide synthase inhibitor—L-NG-nitroarginine methyl ester (L-NAME) 50 mg/Kg.
Analysis of vascular function in isolated mice aorta
Animals received an anesthetic (mixture of ketamine 100 mg/Kg and xylazine 16 mg/Kg; i.p.)
overdose and the thoracic part of the aorta was quickly removed, washed in Krebs-Hanseleit
buffer and carefully dissected from surrounding tissue. Isolated aorta was cut into 4 rings (each
3 mm long) and placed in organ chambers of the wire myograph (620M, Danish Myo Technol-
ogy, Denmark). The rings were mounted between 2 pins attached to an isometric force trans-
ducer with continuous recording of tension (PowerLab, LabChart, ADI Instruments,
Australia) and gassed with 95% O2 and 5% CO2. After an equilibration and heating (37°C)
period of 30 min, the tension was stepwise increased to 10 mN for further stabilization for 30
min. The viability of the vessels was checked by KCl (30–60 mM). Aortic rings were pre-
contracted with increasing concentrations of phenylephrine (PHE, 0.01–1 μM) or prostaglan-
din F2alpha (PGF2α, 0.1–10 μM), respectively, to obtain approximately 80% of KCl induced
contraction. The endothelium-dependent relaxation was induced by cumulative concentra-
tions of acetylcholine (Ach, 0.01–1 μM). Modulatory effect of NO production on contractility
was determined by analyzing the PHE induced contractility before and after the administration
of L-NAME (300 μM, incubation 20 min).
Expression of endothelial dysfunction markers in isolated mice aorta by
Western blot
Samples of aorta (n = 7 controls, n = 6 Sol-Eng+) were homogenized in RIPA lysis buffer
(Sigma-Aldrich, St. Louis, USA) with protease (SERVA Electrophoresis, Germany) and phos-
phatase inhibitors (Thermo Fisher Scientific Inc., IL, USA). Proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrically transferred
onto PVDF membrane (Milipore, NY, USA) using Trans-Blot SD Semi-Dry Electrophoretic
Transfer Cell (Bio-Rad, CA, USA). The membranes were blocked for 1 hour with 5% non-fat
dry milk in Tris buffered saline containing 0.1% Tween-20 at room temperature, and then
incubated with following primary antibodies: goat polyclonal anti-endoglin (90–95 kDa; dilu-
tion 1:500; sc-19793, Santa Cruz Biotechnology, Inc., CA, USA), rabbit polyclonal anti-eNOS
(140kDa; dilution 1:200; sc-654, Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti-
ICAM-1 (85–110 kDa; dilution 1:500; sc-1511-R, Santa Cruz Biotechnology, Inc.), goat poly-
clonal anti-VCAM-1 (140 kDa, dilution 1:500; AF643, R&D Systems). Equal loading of
proteins onto the gel was confirmed by immunodetection of mouse monoclonal anti-GAPDH
antibody (37 kDa; dilution 1:10,000; G8795, Sigma-Aldrich). As secondary antibodies HRP-
conjugated goat anti-mouse IgG at 1:20,000 (A9917, Sigma-Aldrich), HRP-linked goat anti-
rabbit IgG—(Fab)´2 at 1:2,000 (ab6112, Abcam, UK) and HRP-conjugated rabbit anti-goat
IgG at 1:5,000 (A5420, Sigma-Aldrich) were used. Membranes were developed using enhanced
chemiluminescent reagent (Thermo Fisher Scientific Inc.) and subsequently exposed to X-Ray
films (Foma, Czech Republic). The immunoreactive bands were scanned by using an Epson
Perfection V5000 Photo (EPSON Inc., CA, USA) and semiquantified using NIS-Elements soft-
ware, version 4.0 (Laboratory Imaging, Czech Republic).
Urinary nitrite excretion
Urine was obtained from individual mice housed in metabolic cages for 24 h. Urine was collect-
ed in graduated cylinders containing 100 μL of 0.1% sodium azide (to minimize bacterial
growth) and 1 mL of mineral oil (to avoid evaporation). Urinary nitrite concentration was
Soluble Endoglin and Endothelial Dysfunction
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determined in plasma and urine by a modification of the Griess reaction, as described [20].
Briefly, 500 μL of sample were mixed with 250 μL of Griess reagent (1% sulfanilamide and
0.1% naphthyl ethylenediamine dihydrochloride, in 2.5% orthophosphoric acid; Sigma Al-
drich) and incubated for 15 min at room temperature. Absorbance was measured at 560 nm
and calibration was carried out using sodium nitrite. Urine creatinine concentrations were de-
termined by a modification of Jaffé’s reaction method.
Statistical analysis
The statistical analysis was performed by GraphPad Prism 6.0 software (GraphPad Software,
Inc., CA, USA). All data are presented as mean ± S.E.M. Direct group-group comparisons were
carried out using one or two way ANOVA, paired or unpaired t-test and Mann-Whitney test
as adequate. P values of 0.05 or less were considered statistically significant.
RESULTS
Elevated levels of human soluble endoglin in plasma in Sol-Eng+mice
ELISA analysis was used to assess human soluble endoglin levels in studied mice. As shown in
Fig. 1, soluble endoglin concentration in plasma was substantially higher in both female
(2.477 ± 110.3 vs. 54.68 ± 16.64 ng/ml, respectively) and male (2.579 ± 115.2 vs. 37.79 ± 13.95
ng/mL, respectively) Sol-Eng+ mice when compared to control mice (Fig. 1).
Increased arterial pressure in Sol-Eng+ mice
Measurements of AP by tail-cuff method (Table 1) show that systolic pressure in male and fe-
male Sol-Eng+mice is higher than that of control mice. Arterial pressure was also measured by
telemetry, showing that systolic and diastolic AP in Sol-Eng+male mice was higher than that in
control littermates (Fig. 2A). In the same group of animals, no significant differences in HR
were observed between transgenic and control mice (Fig. 2B).
Preserved NO-dependent vascular response in vivo in Sol-Eng+mice
To test the NO-dependent function in vivo, we determined the response of BP to the blockade
of nitric oxide (NO) synthesis and nitrite concentration in the urine. Acute administration of
the NOS inhibitor L-NAME induced a sustained and similar hypertensive response in both
groups of animals (Fig. 3B). Furthermore, acute administration of Ach seems to induce a simi-
lar drop of BP in Sol-Eng+ mice and control animals (data not shown). However, it should be
noted that the effect of acetylcholine with this experimental design was very variable, probably
explained because it is very short and in many cases the hypotensive effect was artifacted by the
removal of the mice from their cages to inject the drug and the consequent effects on arterial
pressure, thus making difficult to correctly assess the hypotensive effect of ACh. Acute admin-
istration of sodium nitroprusside (SNP) also induced a significantly fall of BP in Sol-Eng+ and
control mice (Fig. 3A), with no significant differences between both groups of mice. Urinary
excretion of nitrites, a stable-end product of NO metabolism, was also not statistically different
in Sol-Eng+ vs. control mice (Fig. 4).
Preserved NO-dependent vasodilation in ex vivo aortic rings in Sol-Eng+
mice
Endothelium-dependent vasodilation induced by acetylcholine (Ach) in PHE or PGF2α
(1 μM) pre-contracted aorta was similar in Sol-Eng+ and control female mice and also in Sol-
Eng+ and control male animals (81.18±3.26 vs. 73.65±2.46, 85.01±3.13 vs. 78.9±6.26,
Soluble Endoglin and Endothelial Dysfunction
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respectively) (Fig. 5A). The effect of L-NAME on PHE-induced constriction was also similar in
all experimental groups (females from Sol-Eng+ Δ = 92.17 and control mice Δ = 102.7; males
from Sol-Eng+ Δ = 97.8 and control mice Δ = 124.5) (Fig. 5B).
No change in the expression of markers for endothelial dysfunction in
aorta in Sol-Eng+ mice
Western blot analysis was performed in order to evaluate the changes in the aortic expression
of endoglin, eNOS, ICAM-1 and VCAM-1 between Sol-Eng+ and control groups. Western blot
analysis revealed no significant differences in endoglin and eNOS expression in aorta between
Sol-Eng+ and control mice (Fig. 6A-D). In addition, no changes in the expression of cell adhe-
sion molecules ICAM-1 and VCAM-1 were detected in Sol-Eng+mice in comparison with con-
trol animals (Fig. 6E-H).
Alterations in vascular contractility in female Sol-Eng+mice
In order to evaluate a possible impact of high soluble endoglin levels on aortic function, vascu-
lar contractility was evaluated in Sol-Eng+ and control mice. Receptor-independent vascular
contraction induced by KCl (30 mM) was similar in aorta taken from each experimental group
(control female, Sol-Eng+ female, control male, Sol-Eng+male; Fig. 7A). Also, prostaglandin
F2α (PGF2α)-induced vasoconstriction was not different between Sol-Eng+ and control female
mice (212.3±21.06 vs. 254.2±18.22, respectively) as well as between Sol-Eng+ and control male
mice (254.6±17.87 vs. 254.2±26.57, respectively) (Fig. 7B). In contrast, the vasoconstrictor re-
sponse to phenylephrine (PHE) was significantly reduced in female Sol-Eng+mice when
Fig 1. Concentrations of human soluble endoglin in plasma of Sol-Eng+ and control mice.Human soluble endoglin concentrations in plasma from
female (control n = 53, Sol-Eng+ n = 22) (A) and male (control n = 31, Sol-Eng+ n = 19) (B) mice. Data are shown as mean ± S.E.M. Mann-Whitney test,
***p0.001.
doi:10.1371/journal.pone.0119665.g001
Table 1. Systolic arterial pressure in conscious male and female Sol-Eng+ mice and controls,
assessed by tail cuff.
male female
control Sol-Eng+ control Sol-Eng+
mean 110.5 121.7 108.5 122.2
S.E.M. 1.9 2.3 2.2 4.2
n 10 12 10 11
p 0.05 0.05
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compared to control mice (75.53±15.39 vs. 139.3±7.83, respectively), while in male Sol-Eng+
this response was not altered (123.2±18.98 vs. 132.1±15.23, respectively) (Fig. 7C). Dose-re-
sponse curves for PGF2α and PHE are shown in Fig. 7D and 7E, respectively.
DISCUSSION
A soluble form of endoglin (sEng) was demonstrated to be elevated in the sera of preeclamptic
women, correlating with disease severity [3]. In addition sEng appears to contribute to the
pathogenesis of pre-eclampsia by impairing binding of TGF-β1 to its receptors and down-
stream signaling, including effects on activation of eNOS and vasodilation, suggesting that
sEng deregulate TGF-β signaling in the vasculature and may play a role in vascular dysfunction
[3]. Blann et al. originally detected increased levels of sEng in hypercholesterolemic patients
[6]. These authors proposed that high levels of sEng might be related to development of endo-
thelial dysfunction in patients with hypercholesterolemia because sEng levels correlated with
cholesterol levels [6]. More recently, a positive correlation between sEng plasma levels and
basal glycaemia, glycated hemoglobin, endothelial dysfunction and retinopathy in patients
with type II diabetes, hypertension and patients with high cardiovascular risk was observed [9].
Cui et al. showed that sEng levels and hs-CRP levels are higher in patients with plaque rupture
and unstable plaques when compared with patients with stable atherosclerotic plaques [21].
Fig 2. Blood pressure (A) and heart rate (B) in Sol-Eng+ and control male mice assessed by telemetry. SABP: Systolic arterial blood pressure; DABP:
Diastolic arterial blood pressure; MABP: mean arterial blood pressure. Data are shown as mean ± S.E.M. ANOVA and unpaired t-test with respect to control
mice, *p0.01.
doi:10.1371/journal.pone.0119665.g002
Fig 3. Pressure responses to agonists or antagonists of the NO-cGMP-system in Sol-Eng+ and control mice.Maximal hypotensive effect of sodium
nitroprusside (SNP; 2 mg/Kg b.w.) in Sol-Eng+ and control mice (A). Maximal hypertensive effect of L-NAME (50 mg/Kg b.w.) in Sol-Eng+ and control mice
(B). Effects were measured by telemetry. SABP: Systolic blood arterial pressure. Data are shown as mean ± S.E.M. ANOVA and unpaired t-test with respect
to control, *p0.05; ANOVA and paired t-test with respect to basal conditions, #p0.05.
doi:10.1371/journal.pone.0119665.g003
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Fig 4. Urinary excretion of nitrites in Sol-Eng+ and control mice.Urinary excretion of nitrites was
measured in urine from Sol-Eng+ and control mice collected in metabolic cages, and corrected by creatinine
concentration. Data are shown as mean ± S.E.M. Unpaired t-test.
doi:10.1371/journal.pone.0119665.g004
Fig 5. Endothelium-dependent responses in Sol-Eng+ and control mice. Acetylcholine-induced relaxation in PHE or PGF2α (1 μM) pre-constricted
vessels (A). Effect of L-NAME on the PHE (1 μM)-induced contraction (B). Data are shown as mean ± S.E.M. Mann-Whitney test, unpaired t-test, *p0.05,
***p0.001.
doi:10.1371/journal.pone.0119665.g005
Soluble Endoglin and Endothelial Dysfunction
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Fig 6. Markers of endothelial dysfunction in aorta. Expression of endoglin (A, B), eNOS (C, D), ICAM-1 (E, F) and VCAM-1 (G, H) in total protein extracts
frommice aorta. Equal loading of samples was confirmed by immunodetection of GADPH (A, B). Top: densitometric analysis (control = 100%). Bottom:
representative immunoblots. Data are shown as mean ± S.E.M. Mann-Whitney test, unpaired t-test.
doi:10.1371/journal.pone.0119665.g006
Soluble Endoglin and Endothelial Dysfunction
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Changes of sEng levels were associated with hypercholesterolemia and statin treatment in ex-
perimental atherosclerosis in mice [7,22]. Soluble endoglin was also demonstrated to increase
vascular permeability [3], which is also hallmark of endothelial disturbance. All these studies,
suggest that sEng might be considered as an interesting biomarker associated with hypercho-
lesterolemia/endothelial dysfunction and atherogenesis [11].
On the other hand, a few papers showed that soluble endoglin is not only a biomarker be-
cause high levels of sEng might affect vascular endothelium function. Indeed, administration of
adenoviral sEng in non-pregnant mice resulted in an increased expression of P-selectin, soluble
E-selectin and VCAM-1 levels, increased number of rolling leukocytes in mesenteric venules
and impaired endothelial dependent vascular autoregulation, which was related to neutraliza-
tion of TGF-β signaling [12]. sEng has antiangiogenic properties, and its administration to
mice induced an increase in arterial pressure [5]. As mentioned above it has been suggested
that soluble endoglin interacts with TGF-β1, leading to the inhibition of binding of this protein
to TGF-β receptor complex. These interactions subsequently could result in sEng-induced in-
hibition of TGF-β1-mediated eNOS activation in endothelial cells [1,3]. In addition, binding of
soluble endoglin to BMP9 may affect the Smad1/5 signaling pathway, and, in turn, may alter
Fig 7. Impaired vascular contractility in female Sol-Eng+ mice as compared to control mice.Maximal contraction to KCl (30 mM) (A). Maximal
contraction to PGF2α (10μM) (B) and to PHE (1 μM) (C) in Sol-Eng+ and control mice. Comparison of dose-response to PGF2α (D) and PHE (E) in Sol-Eng+
as compared to control mice. Data are shown as mean ± S.E.M. Unpaired t-test, **p0.01, ***p0.001.
doi:10.1371/journal.pone.0119665.g007
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endothelial function [23]. Moreover, specific binding of a mouse soluble endoglin construct
(mEngECD-mFc 27–581) to human BMP9 and BMP10 was demonstrated recently [24]. This
study suggests that the interaction domains between endoglin and BMP9 are highly conserved
between human and mouse species [24]. Therefore, it is expected that a similar binding be-
tween human endoglin and mouse BMP9 may also occur in our transgenic mice overexpres-
sing human soluble endoglin.
In the light of these data, we hypothesized that high levels of soluble endoglin might induce
endothelial dysfunction in systemic conduit vessels, such as aorta, in transgenic mice that ex-
press high levels of human soluble endoglin (Sol-Eng+) [5].
Sol-Eng+ mice have high plasma concentrations of human soluble endoglin within the range
of 2,000–3,000 ng/mL that are far more elevated when compared to hypercholesterolemic mice
with advanced atherosclerosis, where plasma concentrations of mouse soluble endoglin
amounted to 2,000–3,000 pg/mL [22], which is almost 1000x less than in mice used in this
study. The transgenic littermates that do not develop high levels of human soluble endoglin
were used as controls in this study. It was demonstrated that Sol-Eng+ mice develop a mild hy-
pertension and proteinuria when compared to controls [5]. However, there are no data show-
ing that high levels of soluble endoglin can induce endothelial dysfunction in aorta of
these mice.
Endothelial dysfunction is characterized by the altered vascular relaxation, due to the im-
paired nitric oxide (NO) bioavailability that can be the consequence of either a reduced pro-
duction by endothelial nitric oxide synthase (eNOS) or an increased removal by reactive
oxygen species [13,25]. In addition, NO-deficiency is associated with overexpression of pro-
inflammatory cell adhesion molecules like VCAM-1 and ICAM-1 in endothelial cells [26].
Moreover, decreased expression of tissue endoglin resulted in a reduced eNOS expression lead-
ing to an impaired endothelium-dependent vascular function [27].
In this study, we have observed that conscious mice overexpressing human soluble endoglin
show a normal hypotensive response to acetylcholine and nitroprusside, thus demonstrating a
normal-NO-mediated vascular relaxation. It should be noted that the effect of acetylcholine is
very short and in many cases the hypotensive effect was artifacted by the removal of the mice
from their cages to inject the drug and the consequent effects on arterial pressure, thus making
difficult to correctly assess the hypotensive effect of ACh. Furthermore, although administra-
tion of L-NAME induced a lower increase of arterial pressure in Sol-Eng+ than in control mice,
this effect can be explained by the fact that Sol-Eng+mice already have a high pressure under
basal conditions, and the reflex control of arterial pressure in conscious animals prevented a
further increase. In addition, the endothelium-dependent vasodilation induced by acetylcho-
line in PHE or PGF2α pre-contracted aorta showed no differences between Sol-Eng+ and con-
trol female and male mice. Indeed, the effect of L-NAME on PHE-induced constriction was
also similar in all experimental groups, which means that high levels of sEng do not modify
NO production by eNOS. In addition, Western blot analysis showed no differences in the ex-
pressions of eNOS, endoglin, VCAM-1 and ICAM-1 in aorta of both male and female Sol-Eng+
and control mice. Thus, we might propose that the presence of elevated human soluble endo-
glin levels in plasma does not modulate the expression of membrane endoglin, cell adhesion
molecules or eNOS on aortic endothelium in these mice fed with chow diet. In addition, uri-
nary nitrite excretion, a measurement of whole body NO production, was similar in Sol-Eng+
and control mice. These data clearly demonstrate that high levels of soluble endoglin alone can-
not induce alterations of endothelial function in mice at least in basal
normocholesterolemic conditions.
Despite the lack of changes in the expression of potential markers of endothelial dysfunction
we found an impaired vascular response to PHE-induced contraction but not to PGF2α- or
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KCl-induced contraction in female Sol-Eng+mice, as compared to control female mice. By con-
trast the response in male Sol-Eng+ was not altered. According to the above-mentioned results
we can rule out that endothelium is involved in this impaired vascular contractility of female
Sol-Eng+ mice. We might speculate that specific impairment of α1 adrenergic receptors-
dependent signaling in smooth muscle cells present only in female Sol-Eng+ mice, in addition
to the differential gender-specific hormones, might be involved. This phenomenon however re-
quires a further investigation.
It is of interest to mention that transgenic mice with high levels of soluble endoglin on any
atherosclerotic background (apoE-deficient, LDLR-deficient) are not available and thus we
cannot evaluate whether high levels of soluble endoglin might contribute to endothelial dys-
function in atherosclerosis where hypercholesterolemia and inflammation are also present.
In conclusion, we demonstrate that high concentration of soluble human endoglin in plas-
ma alone is not able to induce endothelial dysfunction in aorta of Sol-Eng+ mice which, howev-
er, does not rule out a possibility that soluble endoglin might contribute to alteration of
endothelial function in combination with hypercholesterolemia and/or inflammation.
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